Malaria Vaccines Market Size, Share, Industry Forecast by 2026 - 2034
REPORT DETAILS
Malaria Vaccines Market Summary
The global malaria vaccines market size was valued at USD 551.9 million in 2025, growing at a CAGR of 12.70% from 2026 to 2034. The rising global incidence of malaria and the introduction of low-cost vaccines by pharmaceutical companies are the key factors driving market growth.
Market Statistics
Key Takeaways
- The RTS,S/AS01 segment accounted for the largest market share in 2024, driven by extensive clinical research and trials demonstrating its efficacy.
- The intramuscular segment dominated the market in 2024. This is primarily because it’s the most widely used route for malaria vaccines.
- North America accounted for the largest market share in 2024, driven by the strong presence of major pharmaceutical companies with major investments in malaria vaccine development programs.
- Middle East & Africa is projected to witness a significant CAGR during the projection period. The considerable malaria burden in the region is expected to drive increased collaborations for developing cost-effective malaria vaccines.
Industry Dynamics
- The rising prevalence of malaria in low-income countries and tropical regions such as the Western Pacific, South America, and Africa is fueling the demand for malaria vaccines.
- Growing funding by government and private organizations for vaccine development is supporting market expansion.
- Increased emphasis on the development of innovative vaccine technologies is expected to provide several market opportunities in the coming years.
- The high cost of drug development and distribution may present challenges to market growth.
AI Impact on Malaria Vaccines Market
- The use of AI aids in the advancement of vaccines for malaria because it allows for faster processing of biological and clinical information.
- AI facilitates the development of vaccines by selecting potential targets and candidates.
- It helps facilitate clinical trials by enabling patient selection and analysis of outcomes.
- AI makes it possible to have disease surveillance and vaccine planning through predictive analytics.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
Malaria is a widespread disease caused by a parasitic infection from the protozoan Plasmodium, which is usually transmitted through the bite of different species of Anopheles mosquitoes. Among the various Plasmodium species, four commonly infect humans as their primary host. These species are P. ovale, P. vivax, P. falciparum, and P. malariae. Malaria vaccines are immunizations designed to combat the Plasmodium parasite that infects humans. RTS,S/AS01, R21/Matrix-M, and PfSPZ are the main types of malaria vaccines.
The rising global incidence of malaria, especially in sub-Saharan Africa and other endemic regions, is driving the malaria vaccines market demand. In addition, the introduction of low-cost vaccines by pharmaceutical companies to make them more accessible in developing nations is supporting the development of the market. Further, growing awareness about the aftereffects of malaria is boosting the adoption of malaria vaccines.
The growing consumer demand for preventive healthcare is one of the major emerging malaria vaccines market trends. Increasing inoculation programs and emphasis on the development of innovative vaccine technologies are projected to provide several malaria vaccines market opportunities during the forecast period.
Market Dynamics
Growing Prevalence of Malaria in Low-Income Countries
The malaria epidemic is spreading, and climate change is creating more favorable conditions for mosquito vectors to thrive. Malaria has primarily affected tropical regions such as South America, Central America, Asia, and Africa. In addition, it is most common in the Western Pacific, the Eastern Mediterranean, and Southeast Asia. Thus, the rising prevalence of malaria in low-income nations is driving the malaria vaccines market development.
Increasing Funding and Investment
The combined efforts from governments, private investors, and international organizations play a crucial role in driving vaccine development. With the rising global demand for malaria vaccines, vaccines adjuvants and increasing investment fueling innovation in vaccine research has encouraged competition within the pharmaceutical industry. Investments and funding also ensure that vaccines are produced at scale and can be delivered effectively to high-risk populations. Thus, the increased funding and investment from both private and public sectors are propelling the malaria vaccines market growth.
Next-Generation Malaria Vaccine Technologies
The advanced malaria vaccine technology is adding value to malaria prevention efforts through the provision of improved protection from malaria infection. Advancements in malaria vaccine technology include the use of recombinant protein vaccine technology, nanoparticle-based delivery technology, mRNA vaccine technology, and genetically modified parasite vaccines. Use of these new techniques in malaria vaccines is meant to result in better specificity in the fight against malaria at various stages in its lifecycle. Moreover, the above innovations assist in faster production and delivery of these vaccines. The prospects of future study into the area of malaria vaccines are promising, especially due to the availability of funds.
Source: Polaris Market Research Analysis
Segment Insights
Malaria Vaccines Market Outlook Based on Vaccine Type
The malaria vaccines market, based on vaccine type, is segmented into PfSPZ; RTS,S/AS01; and R21/Matrix-M. The RTS,S/AS01 segment held the largest share of the market with 58.0% in 2025, owing to the extensive clinical research and trials demonstrating its efficacy. The RTS,S/AS01 vaccine targets the P. falciparum species, which is responsible for causing the most severe malaria cases, especially in children. Further, the rollout of RTS, S/AS01 in various African countries drives the robust growth of the segment.
RTS,S vs R21 Malaria Vaccines
| Factor | RTS,S/AS01 | R21/Matrix-M |
| Type of Vaccine | Protein recombinant vaccine | Protein recombinant vaccine |
| Effectiveness | Moderately effective | Higher effectiveness has been demonstrated |
| Schedule | Four doses | Mutli-dose regimen |
| Production Capacity | Well-developed production capability | Undertaking development of production capacity |
| Deployment Status | Used widely | Applications are rapidly growing |
| Primary Focus | Vaccination among children | Large-scale immunization programs |
Malaria Vaccines Market Evaluation Based on Administration Route
The malaria vaccines market, based on administration route, is bifurcated into subcutaneous and intramuscular. The intramuscular segment led the market with 94.0% in 2025, as it is the most widely used route for malaria vaccines, including R21/Matrix-M and RTS,S/AS01. The intramuscular route introduces the vaccine deep into muscle tissue, where it is slowly absorbed into the bloodstream. The slow delivery ensures consistent dosage and immunological response. Also, malaria vaccines delivered through the intramuscular route have shown a superior ability to induce the production of neutralizing antibodies compared to other routes.
Pediatric Vaccination and Child Health Impact
Pediatric vaccination is a critical component of the world’s efforts to combat malaria because those children younger than five years old represent one of the highest risk groups for acquiring severe cases of malaria. In many parts of the world that have a high prevalence of malaria, malaria is one of the biggest causes of morbidity and mortality in children. For this reason, various governments and health organizations worldwide have begun including malaria vaccines in their pediatric vaccination programs. Vaccines against malaria will help reduce the number of infections and deaths from malaria while also supporting healthy development.
Source: Polaris Market Research Analysis
Regional Analysis
By region, the market report offers malaria vaccines market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America led the global malaria vaccines market share of 34.0% in 2025, owing to the strong presence of major pharmaceutical companies with significant investments in malaria vaccine development programs. Further, the introduction of favorable government regulations supporting malaria vaccine R&D initiatives drives the regional market demand.
The Middle East & Africa malaria vaccines market is projected to witness a significant CAGR of 18.83% from 2026 to 2034. With its considerable malaria burden, the region is likely to witness enhanced collaborations between government and private organizations to develop cost-effective malaria vaccines. The rising focus on improving healthcare infrastructure for vaccine storage and packaging in the region is driving the market growth during the forecast period.
Source: Polaris Market Research Analysis
Key Players and Competitive Insights
Leading market players are investing heavily in research and development to expand their offerings, which will help the malaria vaccines market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments such as innovative vaccine launches, international collaborations, higher investments, vaccines contract manufacturing and mergers and acquisitions between organizations. To expand and survive in a more competitive and rising market environment, market participants must offer cost-effective vaccines.
The malaria vaccines market faces competition from major global players, fueled by rising demand for vaccines from low-income countries. The major players dominate the market with their extensive production capacities and advanced technologies. Competition is further heightened by stringent environmental regulations and the necessity for technological advancements to improve the efficacy of vaccines. A few of the leading market players are Instituto Butantan, Merck, PATH, GSK, Vaxart, Biovac, Pfizer, Inovio Pharmaceuticals, Bharat Biotech, University of Oxford, Intellia Therapeutics, Johnson & Johnson, Sanaria, and Takeda Pharmaceutical Company.
List of Key Players
- Bharat Biotech
- BioNTech SE
- GSK
- HDT Bio Corp.
- Inovio Pharmaceuticals
- Johnson & Johnson
- MalarVx, Inc.
- Novavax, Inc.
- PATH
- Sanaria
- Serum Institute of India Pvt. Ltd.
- Sumaya Biotech GmbH & Co. KG
- University of Oxford
- Vaxart
Malaria Vaccines Industry Developments
- April 2026: The Serum Institute of India (SII) announced a license agreement with the University of Oxford, through Oxford University Innovation (OUI). According to SII, the agreement focuses on developing and manufacturing the new malaria vaccine candidate R78C for use in clinical settings. (source: seruminstitute.com)
- June 2025: Bharat Biotech International Limited (BBIL) and GSK plc revealed their commitment to the Vaccine Alliance (Gavi). According to GSK, it involves the reduction of prices of the RTS,S malaria vaccine by Bharat Biotech. The revised prices will be less than $5 in endemic countries. (source: gsk.com)
- April 2025: The OPT-MVAC Africa–Europe consortium was established to improve malaria vaccine uptake across 14 countries in Central and West Africa. By promoting best practices in vaccine distribution, community engagement, and integrated prevention strategies, the consortium aims to enhance program efficiency and accelerate broader adoption in malaria-endemic regions. (Source: opt-mvac.org)
Malaria Vaccines Market Segmentation
By Vaccine Type Outlook
- PfSPZ
- RTS,S/AS01
- R21/Matrix-M
By Administration Route Outlook
- Subcutaneous
- Intramuscular
By Target Population Outlook
- Travelers to Endemic Areas
- Pregnant Women
- Children Under 5 Years
By Immunization Schedule Outlook
- Single Dose
- Multi-Dose
- Booster Doses
By Development Stage Outlook
- Preclinical
- Clinical Trials
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Malaria Vaccines Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 551.9 million |
| Market Size Value in 2026 | USD 619.7 million |
| Revenue Forecast by 2034 | USD 1,612.30 million |
| CAGR | 12.70% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD million and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Malaria Vaccines Market FAQ's
• The malaria vaccines market size was valued at USD 551.9 million in 2025 and is projected to grow to USD 1,612.30 million by 2034
• The market is projected to register a CAGR of 12.70% from 2026 to 2034.
• North America accounted for the largest region-wise market size of 34.0% in 2025.
• A few of the key players in the market are Bharat Biotech; BioNTech SE; GSK; HDT Bio Corp.; Inovio Pharmaceuticals; Johnson & Johnson; MalarVx, Inc.; Novavax, Inc.; PATH; Sanaria; Serum Institute of India Pvt. Ltd.; Sumaya Biotech GmbH & Co. KG; University of Oxford; Vaxart.
• The RTS,S/AS01 segment accounted for the largest market share of 58.0% in 2025.
• The intramuscular segment dominated the market with 94.0% share in 2025.
Download Sample Report of Malaria Vaccines Market
Please fill out the form to request a customized copy of the research report.
